A carregar...

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine

Orally available disease-modifying drugs for relapsing-remitting multiple sclerosis (MS) represent an unmet need for this chronic and debilitating disease. Among 5 currently investigated drugs at phase 3 clinical stage, promising efficacy data for fingolimod and oral cladribine have recently been pu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Warnke, Clemens, Wiendl, Heinz, Hartung, Hans-Peter, Stüve, Olaf, Kieseier, Bernd C
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2010
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2915536/
https://ncbi.nlm.nih.gov/pubmed/20689698
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!